Ophthalmic Surg Lasers Imaging Retina. 2020 Apr 1;51(4):S44-S49. doi: 10.3928/23258160-20200401-06.
The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR).
RR can be associated with a significant decrease in visual acuity (VA) related to the development of cystoid macular edema, macular ischemia, and proliferative retinopathy leading to neovascular glaucoma.
Anti-VEGF therapy is effective at stabilizing VA in around 80% of patients and achieving reductions in central macular thickness when it is administered using a constant algorithm. Furthermore, consistent prophylactic anti-VEGF therapy reduces the risk of development of RR, neovascularization of the iris, and neovascularization glaucoma.
Future studies are needed to determine the optimal regimen for anti-VEGF therapy according to patient risk factors and likelihood of developing RR. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S44-S49.].
本文旨在回顾抗血管内皮生长因子（VEGF）治疗在放射性视网膜病变（RR）患者中的作用。
RR 可导致视力（VA）显著下降，与囊样黄斑水肿、黄斑缺血和导致新生血管性青光眼的增殖性视网膜病变有关。
抗 VEGF 治疗可使约 80%的患者 VA 稳定，并在采用固定算法时降低中心黄斑厚度。此外，持续预防性抗 VEGF 治疗可降低 RR、虹膜新生血管和新生血管性青光眼的发生风险。
需要进一步研究以确定根据患者的危险因素和 RR 发生可能性制定的抗 VEGF 治疗的最佳方案。[眼科手术激光成像视网膜。2020；51：S44-S49.]。
